Based on the information available to Roche, we can confirm that batch number H0133B01 must be considered a counterfeit product. While the batch number corresponds to the Roche system, the expiry date stated as 10/2014 on the complaint sample is different from the expiry date of the genuine batch, and must therefore represent a counterfeit product. Unfortunately Roche did not receive the complaint samples for testing so we cannot provide more details. Please contact the Kurdistan MoH for further information. The genuine batch was packaged by Roche in Switzerland and sent to France, labelled as Avastin (not the Turkish name Altuzan).
Roches Anti-Counterfeiting Measures As the implications for public health and safety can be high, we take the issue of counterfeiting extremely seriously. Roche has implemented various approaches to combat counterfeiting, these include implementing technical anti-counterfeiting measures relating to the design, packaging and labelling of our products, along with working with authorities on a system to track and trace products from distribution to dispensary. We work closely with health authorities and law enforcement agencies to combat the unsafe distribution of our products through unauthorised sources.
Roche takes very seriously compliance with relevant national and international standards, guidelines and regulations aimed at combating counterfeit active pharmaceutical ingredients (APIs), medicines and diagnostics. We fully support governmental efforts and are committed to cooperating with the authorities whenever one of our products is concerned. Further, we participate in national and international industry and governmental efforts to develop stronger laws and improve enforcement, educate the public and train local officials.
Further information regarding Roches position on counterfeit medicines can be found athttp://www.roche.com/responsibility/business_ethics/counterfeiting.htm